The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

The Foundation for Sarcoidosis Research (FSR) has awarded three pilot grants in the amount of $100,000 each, to Dr. Satish ...

CFO updates stated that Roivant ended the quarter with $5.2 billion in cash and marketable securities, including $500 million authorized for additional share buybacks and $1 billion in stock ...

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

Roivant Sciences Ltd (ROIV) showcases strong financials and strategic advancements while navigating ongoing litigation and competitive pressures.

A teenage girl presented to the hospital emergency department with a three-week history of intermittent frontal headache, which was worse in the morning and associated with nausea, vomiting, lethargy, ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

Efzofitimod, the company's first-in-class biologic immunomodulator, is in clinical development for the treatment of interstitial lung diseases or ILD such as pulmonary sarcoidosis. The posters ...